Krajská nemocnice T. Bati

Autoři originĂĄlnĂ­ho textu: J. Steffel, R. Collins, M. Antz, P. Cornu, L. DestegheTento přeloĹženĂ˝ reprint je publikovĂĄn Českou kardiologickou společnostĂ­ a tvořen textem vybranĂ˝m a přeloĹženĂ˝m Českou kardiologickou společnostĂ­ z textu pĹŻvodně publikovanĂŠho v angličtině v Europace 2021;23:1612–1676, https://doi:10.1093/europace/euab065 („časopise“) vydavatelstvĂ­m Oxford University Press v zastoupenĂ­ EvropskĂŠ kardiologickĂŠ společnosti (European Society of Cardiology, ESC). EP Europace © The European Society of Cardiology 2023VĹĄechna prĂĄva vyhrazena; ŞådnĂĄ část publikace nesmĂ­ bĂ˝t reprodukovĂĄna, uchovĂĄvĂĄna v systĂŠmu pro uchovĂĄnĂ­ a vyhledĂĄvĂĄnĂ­ dat či přenĂĄĹĄena v jakĂŠkoliv formě, elektronicky, mechanicky, kopĂ­rovĂĄnĂ­m, nahrĂĄvĂĄnĂ­m či jinĂ˝m zpĹŻsobem bez předchozĂ­ho pĂ­semnĂŠho svolenĂ­ vydavatele.Pro svolenĂ­ s publikacĂ­ piĹĄte prosĂ­m na e-mail: journals.permissions@oup.com.NĂĄzory vyjĂĄdřenĂŠ v člĂĄnku časopisu reprodukovanĂŠm jako tento reprint jsou nĂĄzory autorĹŻ a přispěvatelĹŻ a nutně nemusejĂ­ odrĂĄĹžet nĂĄzory EvropskĂŠ kardiologickĂŠ společnosti, redakce, redakčnĂ­ rady, Oxford University Press nebo společnostĂ­, jichĹž jsou autoři členy.ZmĂ­nka o obchodnĂ­ch nĂĄzvech, komerčnĂ­ch vĂ˝robcĂ­ch nebo organizacĂ­ch a zahrnutĂ­ inzerĂĄtĹŻ do reprintu neznamenĂĄ schvĂĄlenĂ­ časopisem, redakcĂ­ a redakčnĂ­ radou, Oxford University Press ani společnostĂ­, jichĹž jsou autoři členy. Redakce a vydavatel učinili potřebnĂĄ opatřenĂ­, aby ověřili nĂĄzvy léčiv, dĂĄvkovĂĄnĂ­, vĂ˝sledky experimentĂĄlnĂ­ prĂĄce a klinickĂŠ nĂĄlezy, kterĂŠ byly zveřejněny v časopise. Konečnou zodpovědnost za podĂĄnĂ­ a dĂĄvkovĂĄnĂ­ léčiv zmĂ­něnĂ˝ch v tomto reprintu a interpretaci publikovanĂŠho textu nese lĂŠkař a redakce ani vydavatel nemohou přijmout zodpovědnost za ĹĄkody zpĹŻsobenĂŠ jakoukoli chybou nebo vynechĂĄnĂ­m v časopise nebo v tomto reprintu. ProsĂ­m informujte redakci o jakĂ˝chkoli chybĂĄch.OUP, OPL ani ESC nejsou zodpovědnĂŠ a v ŞådnĂŠm případě neručí za přesnost překladu, za chyby, vynechĂĄnĂ­ nebo nepřesnosti a jakĂŠkoli dĹŻsledky z toho vyplĂ˝vajĂ­cĂ­. Za překlad člĂĄnku a tento reprint zodpovĂ­dĂĄ vĂ˝hradně ČeskĂĄ kardiologickĂĄ společnost.

The worldwide outbreak of the novel 2019 coronavirus disease (COVID-19) has led to recognition of a new immunopathological condition: paediatric inflammatory multisystem syndrome (PIMS-TS). The Czech Republic (CZ) suffered from one of the highest incidences of individuals who tested positive during pandemic waves. The aim of this study was to analyse epidemiological, clinical, and laboratory characteristics of all cases of paediatric inflammatory multisystem syndrome (PIMS-TS) in the Czech Republic (CZ) and their predictors of severe course. We performed a retrospective-prospective nationwide observational study based on patients hospitalised with PIMS-TS in CZ between 1 November 2020 and 31 May 2021. The anonymised data of patients were abstracted from medical record review. Using the inclusion criteria according to World Health Organization definition, 207 patients with PIMS-TS were enrolled in this study. The incidence of PIMS-TS out of all SARS-CoV-2-positive children was 0.9:1,000. The estimated delay between the occurrence of PIMS-TS and the COVID-19 pandemic wave was 3 weeks. The significant initial predictors of myocardial dysfunction included mainly cardiovascular signs (hypotension, oedema, oliguria/anuria, and prolonged capillary refill). During follow-up, most patients (98.8%) had normal cardiac function, with no residual findings. No fatal cases were reported.Conclusions: A 3-week interval in combination with incidence of COVID-19 could help increase pre-test probability of PIMS-TS during pandemic waves in the suspected cases. Although the parameters of the models do not allow one to completely divide patients into high and low risk groups, knowing the most important predictors surely could help clinical management.What is Known:• Preliminary evidence, majority from relatively small, and mostly single-centre patient cohorts, has shown some insights in the basic epidemiological and clinical data of children with a paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS).What is New:• To our knowledge, this is the unique published national population-wide cohort allowing to study the epidemiology (including overall incidence), time gap between viral exposure and clinical symptoms of PIMS-TS, and clinical presentations and outcomes within the individual pandemic waves of COVID-19 that were characterised by various prevailing genetic variants of SARS-CoV-2.• We estimated 3-week interval as a most probable period between SARS-CoV-2 infection and PIMS-TS based on nationwide population data using cross-correlation method.Supplementary InformationThe online version contains supplementary material available at 10.1007/s00431-022-04593-7.

Chirurgické oddělení,

Sub-analysis of a retrospective nation-wide observational analysis of heart failure (HF) epidemiology reported to the Czech National Registry of Reimbursed Health Services between 2012 and 2018 aimed at beta-blockers (BBs) utilization. The beta-blockers were generally used in 81.8% of all patients treated for HF in 2012 (n=52 140); 81.8% in 2013 (n=53 058); 83.1% in 2014 (n=56 221); 82.1% in 2015 (n=57 421); 83.3% in 2016 (n=59 187); 82.2% in 2017 (60 058) and in 81.4% in 2018 (n=60 966). In 2018, the majority of patients treated for HF were prescribed metoprolol (22 974; 30.7%) and bisoprolol (21 001; 28%). Carvedilol was prescribed in 7 331 patients treated for HF (9.8%), nebivolol in 5 392 HF patients. Despite its primary indication, betaxolol was used in 2 341 patients treated for HF (3.1%). All other beta-blockers were used in less than 1% of HF patients. In some of the mostly used BBs, their prescription in patients treated for HF changed in the last years (metoprolol 32.4% in 2012, 30.7% in 2018; bisoprolol 20.3% in 2012, 28% in 2018; carvedilol 18.3% in 2012, 9.8% in 2018; nebivolol 2.5% in 2012, 7.2% in 2018; betaxolol 4.2% in 2012, 3.1% in 2018). In an analysis of beta-blockers utilization in all patients treated for heart failure in the given year in the whole country, we have found only slightly lower amount of drug prescription in comparison with specific heart failure registries. This indicates a good translation of current standard of care into common clinical practice. Metoprolol remained the mostly prescribed drug. The prescription of bisoprolol and nebivolol has increased at the expense of carvedilol.

Acta Carpathica Occidentalis, peer-reviewed scientific journal - results of original natural science research in natural sciences, especially from the Carpathian region of the Czech and Slovak Republics.